Over the past two decades, personalized medicine has evolved from a scientific vision to a standard of care for various disease states. With the expanding knowledge in genetics and genomics, precision therapies for cancers and chronic illnesses have advanced. As the shift from one-size-fits-all medicines to personalized treatments based on a person's unique genetic makeup has accelerated, distribution and delivery models are also changing.
AeroSafe is a New York-based cold-chain technology company that provides solutions such as packaging, logistics and supply chain management for the biopharma industry.